{"preliminary_commentary":{"by_channel":{"youtube":3,"podcast":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05912244","nct_id":"NCT05912244","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05912244. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"All patients will be treated with nivolumab-relatlimab FDC on Day 1 of every 28-day cycle for up to two years. Patients will be treated with IO102/IO103 on Days 1 and 15 of the first two 28-day cycles, then on Day 1 of subsequent cycles for up to two total years of treatment.","label":"IO102/IO103, Nivolumab, and Relatlimab","type":"EXPERIMENTAL"}],"collaborators":["IO Biotech"],"completion_date":{"date":"2027-06-09","type":"ESTIMATED"},"conditions":["Melanoma"],"enrollment":{"count":43,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"IO102/IO103","otherNames":[],"type":"DRUG"},{"name":"Nivolumab-Relatlimab","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-01","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase II Study of IO102/IO103 and Nivolumab-relatlimab Fixed Dose Combination in Untreated, Unresectable Stage III/IV Melanoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR)","timeFrame":"3 years"}],"references":[{"citation":"Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmstrom MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.","pmid":"34887574","type":"BACKGROUND"},{"citation":"Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Andersen MH, Marie Svane I. Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023 May;11(5):e006755. doi: 10.1136/jitc-2023-006755.","pmid":"37217243","type":"BACKGROUND"}],"start_date":{"date":"2023-06-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","url":"https://clinicaltrials.gov/study/NCT05912244"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05912244"}